drugset
drugset / Trial / NCT05405257

Oxytocin for Hypermobile Ehlers-Danlos Syndrome

NCT05405257 ↗

Phase 1/2 Terminated 2 enrolled Baylor College of Medicine
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this pilot study is to evaluate effect of IV oxytocin on chronic pain in patients with Hypermobile Ehlers Danlos syndrome.

Timeline

Start
2022-05-13
Primary completion
2025-03-11
Completion
2025-03-11

Outcome

Outcome not reported

Stopped (Enrollment): “Study team has decided to close the trial (NCT05405257) due problems with patient recruitment and enrollment efforts. To date, only one patient completed both arms.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxytocin Peptide 1 iu Intravenous

Indications

Ehlers-Danlos syndrome, hypermobility type